Dimensional Fund Advisors
TVTX icon

Dimensional Fund Advisors’s Travere Therapeutics TVTX Stock Holding History

Dimensional Fund Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-56,681
Closed -$437K – 3410
2024
Q1 		$437K Buy
56,681
+702
+1% +$5.92K ﹤0.01% 3066
2023
Q4 		$503K Buy
55,979
+27
+0% +$197 ﹤0.01% 3043
2023
Q3 		$500K Buy
55,952
+2,039
+4% +$28.8K ﹤0.01% 3044
2023
Q2 		$828K Sell
53,913
-264
-0.5% -$4.8K ﹤0.01% 2956
2023
Q1 		$1.22M Sell
54,177
-49,420
-48% -$1.05M ﹤0.01% 2860
2022
Q4 		$2.18K Sell
103,597
-426,494
-80% -$9.04M ﹤0.01% 2710
2022
Q3 		$13.1M Sell
530,091
-333,969
-39% -$8.63M 0.01% 2046
2022
Q2 		$20.9M Sell
864,060
-234,998
-21% -$5.91M 0.01% 1837
2022
Q1 		$28.3M Buy
1,099,058
+40,555
+4% +$1.08M 0.01% 1786
2021
Q4 		$32.9M Buy
1,058,503
+88,033
+9% +$2.48M 0.01% 1699
2021
Q3 		$23.5M Sell
970,470
-176,356
-15% -$3.24M 0.01% 1915
2021
Q2 		$16.7M Sell
1,146,826
-84,684
-7% -$1.67M 0.01% 2122
2021
Q1 		$30.7M Buy
1,231,510
+39,798
+3% +$1.1M 0.01% 1786
2020
Q4 		$32.5M Sell
1,191,712
-8,554
-0.7% -$200K 0.01% 1704
2020
Q3 		$22.2M Sell
1,200,266
-20,414
-2% -$397K 0.01% 1795
2020
Q2 		$24.9M Buy
1,220,680
+24,155
+2% +$385K 0.01% 1743
2020
Q1 		$17.5M Sell
1,196,525
-43,356
-3% -$652K 0.01% 1841
2019
Q4 		$17.6M Sell
1,239,881
-788
-0.1% -$10.1K 0.01% 2107
2019
Q3 		$14.4M Sell
1,240,669
-319
-0% -$5.27K 0.01% 2180
2019
Q2 		$24.9M Buy
1,240,988
+28,611
+2% +$565K 0.01% 1921
2019
Q1 		$27.4M Buy
1,212,377
+57,518
+5% +$1.27M 0.01% 1878
2018
Q4 		$26.1M Buy
1,154,859
+67,834
+6% +$1.69M 0.01% 1836
2018
Q3 		$31.2M Buy
1,087,025
+164,982
+18% +$4.72M 0.01% 1858
2018
Q2 		$25.1M Sell
922,043
-3,749
-0.4% -$99.8K 0.01% 1987
2018
Q1 		$20.7M Buy
925,792
+15,989
+2% +$381K 0.01% 2039
2017
Q4 		$19.2M Buy
909,803
+12,988
+1% +$297K 0.01% 2081
2017
Q3 		$22.3M Buy
896,815
+71,562
+9% +$1.58M 0.01% 1986
2017
Q2 		$16M Buy
825,253
+271,551
+49% +$4.93M 0.01% 2142
2017
Q1 		$10.2M Buy
553,702
+193,432
+54% +$3.78M ﹤0.01% 2315
2016
Q4 		$6.82M Buy
360,270
+75,221
+26% +$1.54M ﹤0.01% 2455
2016
Q3 		$6.38M Buy
285,049
+228,786
+407% +$4.36M ﹤0.01% 2436
2016
Q2 		$1M Buy
56,263
+24,749
+79% +$401K ﹤0.01% 2921
2016
Q1 		$430K Buy
+31,514
New +$478K ﹤0.01% 3071
2015
Q4 		– Sell
-12,369
Closed -$251K – 3344
2015
Q3 		$251K Hold
12,369
– – ﹤0.01% 3215
2015
Q2 		$410K Hold
12,369
– – ﹤0.01% 3169
2015
Q1 		$296K Sell
12,369
-7,592
-38% -$116K ﹤0.01% 3177
2014
Q4 		$244K Buy
+19,961
New +$207K ﹤0.01% 3226

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Dimensional Fund Advisors's TVTX Position: Q2 2024 in Review

Dimensional Fund Advisors sold out of Travere Therapeutics (TVTX) in Q2 2024, closing a stake of 56,681 shares — an estimated $437K sold.

Dimensional Fund Advisors first reported a position in TVTX in Q4 2014 and held it in 37 quarters. The position peaked at $32.9M in Q4 2021. 173 funds tracked by Wall St. Rank hold TVTX as of Q2 2024.

  • Dimensional Fund Advisors reported no remaining Travere Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Dimensional Fund Advisors sold 56,681 Travere Therapeutics shares in Q2 2024, an estimated $437K.
  • Dimensional Fund Advisors first reported a position in Travere Therapeutics in Q4 2014 and held it in 37 quarters.
  • Dimensional Fund Advisors's Travere Therapeutics position peaked at $32.9M in Q4 2021.
  • 173 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2024.

Based on Dimensional Fund Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.